IL32 and cancer: Previous studies consistently demonstrate that TKIs target the Src‐Akt signaling pathway, a critical downstream target essential for their impact on cancer cell survival.[27, 34] Moreover, it is recognized that an unidentified signal triggering Src‐mediated Akt activation influences TKI sensitivity in cancer cells.[27c] Our findings demonstrate that PCs can circumvent the inhibitory effect of TKIs on Src‐Akt signaling through IL32‐β5‐integrin paracrine signaling.